西

Giuseppe Remuzzi1, Carlos Chiurchiu, Mauro Abbate

  • 1Ospedali Riuniti Di Bergam, Unit of Nephrology and Dialysis, Aldo and Cele Daccò Clinical Research Centre for Diseases, Mario Negri Institute for Parmacological Research, Via Gavazzeni 1124125, Bergamo, Italy. gremuzzi@marionegri.it

Lancet (London, England)
|October 2, 2002
PubMed
概括

作为B细胞疗法之一的Rituximab在患有异常性膜性腎病症的患者中显著降低了蛋白尿. 与其他免疫抑制剂相比,这种治疗显示出有利的短期风险益处概况.